Cyclopharm is an established Australian radiopharmaceutical company servicing the global medical community since 1986.

Cyclopharm is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name of TECHNEGASTM.

TECHNEGASTM has become the industry gold-standard in diagnostic functional lung imaging technology.

We distribute our products in 57 countries throughout the world with over 1500 nuclear medicine departments utilising TECHNEGASTM.

To date, over 4.2 million patient procedures are recorded.

Latest Media Releases

CYC First Half Trading Update

02/07/2021 08:20:00

Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on its trading performance for first half of 2021. Following a review of the company’s unaudited management accounts…

Cyclopharm USFDA Update

28/06/2021 08:22:00

Cyclopharm Limited (ASX: CYC) announcesthat the US Food and Drug Administration (USFDA) has provided a Complete Response Letter (CRL) for the New Drug Application (NDA) for TechnegasTM. The USFDA ha…

Cyclopharm Amended Constitution

04/05/2021 14:36:00

Please find attached CYC’s Amended Constitution adopted by special resolution at today’s Annual General Meeting.  For more information, download the attached PDF.

Latest News